Tamir Biotechnology Inc. (ACEL)

[Perris]

Sidransky's other company - CSBR:
LINK:
http://www.championsbiotechnology.com/ne...

Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs


Last update: 8:30 a.m. EDT May 7, 2008Print E-mail RSS Disable Live Quotes

ARLINGTON, Va., May 7, 2008 /PRNewswire-FirstCall via COMTEX/ -- Champions Biotechnology, Inc. (CSBR:CSBR
News, chart, profile, more

CSBR, , ) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that it has established an agreement with ImClone Systems Incorporated for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline. As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts(TM) in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "ImClone Systems has an impressive antibody pipeline and we are pleased to be working with them to evaluate such promising oncology therapeutic candidates."
For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com .
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits Champions Biotechnology to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.